1-6 of 6
Surai Jones
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)

Ian W. Flinn, MD PhD, John G. Gribben, MDDSc FMedSci, Martin J.S. Dyer, William G Wierda, MD PhD, Michael B. Maris, Richard R. Furman, MD, Peter Hillmen, MBChB, PhD, Jeffrey Jones, MD, Swami P. Iyer, MD, Surai Jones, Yanwen Jiang, Daniela Soriano Pignataro, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 430.
https://doi.org/10.1182/blood.V130.Suppl_1.430.430
Published: 2017
Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2016) 128 (22): 622.
https://doi.org/10.1182/blood.V128.22.622.622
Published: 2016
Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles
Journal: Blood
Blood (2016) 128 (22): 1853.
https://doi.org/10.1182/blood.V128.22.1853.1853
Published: 2016
Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Andres Forero-Torres, MD, Kathryn S. Kolibaba, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Calvin Lee, Jeff Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1856.
https://doi.org/10.1182/blood.V128.22.1856.1856
Published: 2016
Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation

Nancy L. Bartlett, Andy I Chen, MD PhD, Kathryn S. Kolibaba, Thierry Lamy, MDPhD, Surai Jones, Jamie Hirata, Jeff P. Sharman, MD
Journal: Blood
Blood (2015) 126 (23): 2726.
https://doi.org/10.1182/blood.V126.23.2726.2726
Published: 2015
Journal Articles

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Franck Morschhauser, MD PhD, Ian Flinn, Ranjana H Advani, MD, Catherine S. Diefenbach, MD, Kathryn Kolibaba, MD, Oliver W. Press, MD PhD, Laurie H Sehn, MD MPH, Andy I Chen, MDPhD, Gilles Salles, MD PhD, Herve Tilly, MD, Bruce D. Cheson, MD, Sarit Assouline, MD MSc, Martin Dreyling, Anton Hagenbeek, MD PhD, Pier Luigi Zinzani, MD, Sreeni Yalamanchili, BSPharm, Dan Lu, PhD, Cheryl Jones, PhD, Surai Jones, PhD, Yu-Waye Chu, Jeff P. Sharman, MD
Journal: Blood
Blood (2014) 124 (21): 4457.
https://doi.org/10.1182/blood.V124.21.4457.4457
Published: 2014